financetom
Business
financetom
/
Business
/
U-Haul Fiscal Q2 Earnings Decline, Revenue Rises
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
U-Haul Fiscal Q2 Earnings Decline, Revenue Rises
Nov 9, 2024 11:47 AM

05:46 PM EST, 11/06/2024 (MT Newswires) -- U-Haul Holding ( UHAL ) reported fiscal Q2 diluted earnings late Wednesday of $0.91 per share, down from $1.36 a year earlier.

A lone analyst polled by Capital IQ expected $1.32.

Revenue in the quarter ended Sept. 30 was $1.66 billion, up from $1.65 billion a year earlier.

A lone analyst surveyed by Capital IQ expected $1.69 billion.

U-Haul shares were down 3% in after-hours activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Form 8.3
Form 8.3
Nov 13, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Form 8.3
Form 8.3
Nov 13, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Medical device maker Biofrontera Q3 revenue falls more than expected on advanced purchases in 2024
Medical device maker Biofrontera Q3 revenue falls more than expected on advanced purchases in 2024
Nov 13, 2025
Overview * Biofrontera Q3 revenue of $7 mln missed analyst expectations due to advanced purchases in 2024 * Adjusted EBITDA for Q3 was negative $6 mln, missing analyst estimates * Company completed purchase of US Ameluz and RhodoLED assets, reducing royalty payments Outlook * Company anticipates substantial 4Q25 and annual revenue growth due to price normalization * Biofrontera expects enhanced...
Form 8.3
Form 8.3
Nov 13, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved